Eric Venker
President at ROIVANT SCIENCES LTD.
Net worth: 5 M $ as of 2024-04-29
Eric Venker active positions
Companies | Position | Start | End |
---|---|---|---|
IMMUNOVANT, INC. | Director/Board Member | 2020-02-17 | - |
ROIVANT SCIENCES LTD. | Chief Operating Officer | 2018-10-31 | - |
President | 2020-12-31 | - | |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Chief Operating Officer | 2018-10-31 | - |
President | 2020-12-31 | - | |
Corporate Officer/Principal | 2016-12-31 | 2018-10-31 | |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Director/Board Member | - | - |
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Director/Board Member | - | - |
Chief Operating Officer | - | - | |
Roivant Social Ventures, Inc. | Director/Board Member | 2013-12-31 | - |
Career history of Eric Venker
Former positions of Eric Venker
Companies | Position | Start | End |
---|---|---|---|
SIO GENE THERAPIES INC. | Director/Board Member | 2020-02-16 | 2023-04-04 |
ARBUTUS BIOPHARMA CORPORATION | Director/Board Member | 2020-01-31 | 2022-05-24 |
Independent Dir/Board Member | 2020-01-31 | 2022-05-24 | |
ROIVANT SCIENCES LTD. | Chief Operating Officer | - | - |
President | - | - | |
░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Eric Venker
St. Louis College of Pharmacy | Doctorate Degree |
Yale School of Medicine | Doctorate Degree |
Statistics
International
United States | 11 |
United Kingdom | 2 |
Switzerland | 2 |
Operational
Director/Board Member | 6 |
Chief Operating Officer | 4 |
President | 3 |
Sectoral
Health Technology | 8 |
Consumer Services | 4 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
ARBUTUS BIOPHARMA CORPORATION | Health Technology |
ROIVANT SCIENCES LTD. | Health Technology |
IMMUNOVANT, INC. | Health Technology |
Private companies | 6 |
---|---|
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Sio Gene Therapies, Inc.
Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
Montes Archimedes Acquisition Corp.
Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Montes Archimedes Acquisition Corp operates as a blank check company. It is formed for the business purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded James C. Momtazee and Maria C. Walker on July 6, 2020 and is headquartered in Menlo Park, CA. | Finance |
Roivant Social Ventures, Inc. |
- Stock Market
- Insiders
- Eric Venker
- Experience